Full Text View
Tabular View
No Study Results Posted
Related Studies
Aggrastat Truncated Length Against Standard Therapies in Percutaneous Coronary Intervention (ATLAST-PCI)
This study has suspended participant recruitment.
Study NCT01245725   Information provided by Medicure

First Received on November 12, 2010.   Last Updated on January 18, 2012   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Myocardial Infarction
Acute Coronary Syndromes
Unstable Angina
Percutaneous Coronary Intervention
Additional conditions recognized in this trial
Acute Coronary Syndrome
Angina, Unstable
Infarction
More general conditions related to this trial
Angina Pectoris
Cardiovascular Diseases
Chest Pain
Heart Diseases
Ischemia
Myocardial Ischemia
Necrosis
Pain
Pathologic Processes
Signs and Symptoms
Vascular Diseases
Interventions listed in this trial
Tirofiban (Aggrastat)
Placebo
Additional drug interventions recognized in this trial
Tirofiban
More general drug interventions related to this trial
Cardiovascular Agents
Fibrin Modulating Agents
Fibrinolytic Agents
Hematologic Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Platelet Aggregation Inhibitors
Therapeutic Uses
Sponsors listed in this trial
Medicure
Sarah Cannon Research Institute


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services